Dec 4, 2017
Marty Driscoll, CEO of Spring Bank Pharmaceuticals, discusses treatments for the hepatitis B virus, a disease suffered by 250 million people globally who are chronically infected with the hepatitis B virus. Marty talks about what a functional cure for chronically infected patients means, and what Spring Bank is doing to help those affected. Spring Bank is developing a new oral drug named inarigivir that is a selective immunomodulator/encapsidation inhibitor. Inarigivir could become a key component of a future safe and simple combination treatment in an effort to substantially increase functional cure rates for patients with chronic hepatitis B and reduce their need for daily drugs.
#HBV #HepatitisB #Functionalcure #inarigivir